iptacopan

FDA Drug Profile — FABHALTA

iptacopan is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including FABHALTA. Available dosage forms: capsule, powder.

Drug details

Generic Name
iptacopan
Brand Names
FABHALTA
Application Number
NDA218276
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
4
Dosage Forms
CAPSULE, POWDER
Routes
ORAL
Active Ingredients
IPTACOPAN HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. ( 1.2 ) the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). 1.2 Immunoglobulin A Nephropathy FABHALTA is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 1.3 Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.